Literature DB >> 18781678

The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.

Anthony H V Schapira1.   

Abstract

Levodopa is the 'gold standard' drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781678     DOI: 10.1002/mds.22146

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

1.  Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats.

Authors:  Masoud Alirezaei; Zeynab Khoshdel; Omid Dezfoulian; Marzyeh Rashidipour; Vahideh Taghadosi
Journal:  J Physiol Sci       Date:  2015-02-11       Impact factor: 2.781

2.  Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.

Authors:  M Rieck; A F Schumacher-Schuh; V Altmann; S M Callegari-Jacques; C R M Rieder; M H Hutz
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

3.  Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.

Authors:  Monica Colamartino; Massimo Santoro; Guglielmo Duranti; Stefania Sabatini; Roberta Ceci; Antonella Testa; Luca Padua; Renata Cozzi
Journal:  Neurotox Res       Date:  2014-10-30       Impact factor: 3.911

Review 4.  mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.

Authors:  Corey R Hopkins; Craig W Lindsley; Colleen M Niswender
Journal:  Future Med Chem       Date:  2009-06       Impact factor: 3.808

5.  Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence.

Authors:  Maryam Rezaei; Masoud Alirezaei
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

Review 6.  [Pharmacological treatment of motor symptoms in Parkinson's diseases].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

7.  Trends in inpatient antiparkinson drug use in the USA, 2001-2012.

Authors:  James A G Crispo; Yannick Fortin; Dylan P Thibault; Matthew Emons; Lise M Bjerre; Dafna E Kohen; Santiago Perez-Lloret; Donald Mattison; Allison W Willis; Daniel Krewski
Journal:  Eur J Clin Pharmacol       Date:  2015-06-18       Impact factor: 2.953

8.  Impairment of neuronal mitochondrial function by L-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage.

Authors:  Philipp Hörmann; Sylvie Delcambre; Jasmin Hanke; Robert Geffers; Marcel Leist; Karsten Hiller
Journal:  Cell Death Discov       Date:  2021-06-28

9.  Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.

Authors:  Li Xie; Li-Fang Hu; Xing Qi Teo; Chi Xin Tiong; Valerio Tazzari; Anna Sparatore; Piero Del Soldato; Gavin Stewart Dawe; Jin-Song Bian
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

Review 10.  Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease.

Authors:  Sushruta Koppula; Hemant Kumar; Sandeep Vasant More; Byung Wook Kim; In Su Kim; Dong-Kug Choi
Journal:  Int J Mol Sci       Date:  2012-08-23       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.